Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines
NCT ID: NCT04954651
Last Updated: 2022-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1000 participants
OBSERVATIONAL
2021-07-07
2022-03-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunogenicity of the BNT162b2 Covid-19 Vaccine in Elderly People Aged 85 and Older in Greece
NCT04756817
Immunity After COVID-19 Vaccination
NCT04924855
Immunity After COVID-19 Vaccination
NCT04883164
Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations
NCT03145324
B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency
NCT04954469
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VAC
Vaccinated subject against Sars-Cov2
Approved vaccines against Sars-Cov2
Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Approved vaccines against Sars-Cov2
Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who do not provide info on their health status
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Patras
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ioannis Habeos
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ioannis Habeos, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Patras
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Patras
Pátrai, , Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Parthymou A, Habeos EE, Habeos GI, Deligakis A, Livieratos E, Marangos M, Chartoumpekis DV. Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece. BMJ Open. 2022 May 19;12(5):e057084. doi: 10.1136/bmjopen-2021-057084.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
99-25/2/2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.